Citigroup’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-563
| Closed | -$12.2K | – | 6042 |
|
|
2022
Q4 | $12.2K | Sell |
563
-337
| -37% | -$7.12K | ﹤0.01% | 4779 |
|
|
2022
Q3 | $17K | Sell |
900
-58,423
| -98% | -$1.21M | ﹤0.01% | 4808 |
|
|
2022
Q2 | $1.18M | Buy |
59,323
+50,586
| +579% | +$1.33M | ﹤0.01% | 2524 |
|
|
2022
Q1 | $261K | Sell |
8,737
-43,449
| -83% | -$1.27M | ﹤0.01% | 3916 |
|
|
2021
Q4 | $1.22M | Buy |
52,186
+24,087
| +86% | +$640K | ﹤0.01% | 3058 |
|
|
2021
Q3 | $877K | Sell |
28,099
-18,347
| -40% | -$568K | ﹤0.01% | 3188 |
|
|
2021
Q2 | $1.63M | Sell |
46,446
-14,687
| -24% | -$478K | ﹤0.01% | 2835 |
|
|
2021
Q1 | $2.15M | Buy |
61,133
+57,679
| +1,670% | +$2.13M | ﹤0.01% | 2438 |
|
|
2020
Q4 | $130K | Buy |
3,454
+2,809
| +436% | +$102K | ﹤0.01% | 5327 |
|
|
2020
Q3 | $22K | Sell |
645
-1,152
| -64% | -$33.6K | ﹤0.01% | 6149 |
|
|
2020
Q2 | $48K | Sell |
1,797
-1,296
| -42% | -$30.6K | ﹤0.01% | 6044 |
|
|
2020
Q1 | $51K | Buy |
3,093
+911
| +42% | +$20K | ﹤0.01% | 5969 |
|
|
2019
Q4 | $55K | Buy |
2,182
+883
| +68% | +$17.7K | ﹤0.01% | 6229 |
|
|
2019
Q3 | $26K | Sell |
1,299
-1,594
| -55% | -$41.3K | ﹤0.01% | 6575 |
|
|
2019
Q2 | $94K | Buy |
2,893
+591
| +26% | +$19.8K | ﹤0.01% | 5937 |
|
|
2019
Q1 | $74K | Sell |
2,302
-137
| -6% | -$3.69K | ﹤0.01% | 6025 |
|
|
2018
Q4 | $60K | Sell |
2,439
-63
| -3% | -$1.67K | ﹤0.01% | 6092 |
|
|
2018
Q3 | $82K | Buy |
2,502
+794
| +46% | +$26K | ﹤0.01% | 6089 |
|
|
2018
Q2 | $61K | Buy |
+1,708
| New | +$55.3K | ﹤0.01% | 6135 |
|
|
2016
Q2 | – | Sell |
-2
| Closed | – | – | 7553 |
|
|
2016
Q1 | $0 | Buy |
+2
| New | +$18 | ﹤0.01% | 7871 |
|
|
2015
Q3 | – | Sell |
-10
| Closed | – | – | 7842 |
|
|
2015
Q2 | $0 | Buy |
+10
| New | +$336 | ﹤0.01% | 7834 |
|
|
2015
Q1 | – | Sell |
-25
| Closed | -$1K | – | 7509 |
|
|
2014
Q4 | $1K | Sell |
25
-25
| -50% | -$1.1K | ﹤0.01% | 7012 |
|
|
2014
Q3 | $3K | Hold |
50
| – | – | ﹤0.01% | 6751 |
|
|
2014
Q2 | $3K | Sell |
50
-60
| -55% | -$4.17K | ﹤0.01% | 6661 |
|
|
2014
Q1 | $9K | Buy |
110
+93
| +547% | +$8.46K | ﹤0.01% | 6394 |
|
|
2013
Q4 | $1K | Buy |
+17
| New | +$1.25K | ﹤0.01% | 6890 |
|
Other funds holding ALBO
Citigroup's ALBO Position: Q1 2023 in Review
Citigroup sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 563 shares — an estimated $12.2K sold.
Citigroup first reported a position in ALBO in Q4 2013 and held it in 26 quarters. The position peaked at $2.15M in Q1 2021. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Citigroup reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Citigroup sold 563 Albireo Pharma Inc shares in Q1 2023, an estimated $12.2K.
- Citigroup first reported a position in Albireo Pharma Inc in Q4 2013 and held it in 26 quarters.
- Citigroup's Albireo Pharma Inc position peaked at $2.15M in Q1 2021.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.